We reply within one business dayGet my quote
Chronic rhinosinusitis with nasal polyps (CRSwNP): US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Nasal polyps (CRSwNP): the short answer
The US FDA has approved four medicines on this page for nasal polyps (CRSwNP), each for specific patients. Four of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Dupixent, Nucala, Xolair and Tezspire.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is nasal polyps (CRSwNP)?
Nasal polyps are soft, sac-like growths on the lining of the nose or sinuses. They are not cancer. They seem to grow because of long-term swelling and inflammation from allergies, asthma or infection. When they occur with long-lasting sinus inflammation, doctors call it chronic rhinosinusitis with nasal polyps (CRSwNP).[1]
Small polyps may cause no symptoms. Larger ones can block the nose and sinuses and cause a runny or stuffy nose, a blocked feeling, loss of smell and taste, snoring and, with infection, headache and facial pain. People with aspirin sensitivity, asthma, chronic sinus infections, cystic fibrosis or hay fever are more likely to get them.[1]
An ear, nose and throat specialist examines the nose, often with nasal endoscopy and a CT scan. Treatment starts with steroid nasal sprays and may include surgery. In the US, several biologic injections are approved as add-on treatment when CRSwNP is not controlled.[1, 2]
Nasal polyps (CRSwNP) in the Gulf
Among 660 patients with chronic rhinosinusitis at King Abdulaziz University Hospital in Saudi Arabia, 67.7% had nasal polyps, 32% had asthma and 10% had aspirin hypersensitivity. CRSwNP was most common in people over 50.[3]
US FDA-approved medicines for nasal polyps (CRSwNP)
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Dupixent (dupilumab)
FDA-approved for add-on maintenance treatment of inadequately controlled CRSwNP in adults and children 12 years and older. It is an injection under the skin. It is also approved for asthma, eczema and other conditions.[2]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[4, 5]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Lebanon, India, Pakistan - Nucala (mepolizumab)
FDA-approved for add-on maintenance treatment of CRSwNP in adults 18 years and older with an inadequate response to nasal corticosteroids. It is an injection under the skin.[6]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[4, 5]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan - Xolair (omalizumab)
FDA-approved for add-on maintenance treatment of CRSwNP in adults 18 years and older with an inadequate response to nasal corticosteroids. It is an injection under the skin.[7]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[4, 5]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan - Tezspire (tezepelumab-ekko)
FDA-approved for add-on maintenance treatment of inadequately controlled CRSwNP in adults and children 12 years and older. It is an injection under the skin. It is also approved for severe asthma.[8]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[4, 5]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, India, Pakistan
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[9, 10] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for nasal polyps (CRSwNP)
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for nasal polyps (CRSwNP)?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Dupixent, Nucala, Xolair and Tezspire. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Dupixent available in Saudi Arabia or the UAE?
Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Dupixent?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Are nasal polyps cancer?
No. MedlinePlus explains that nasal polyps are not cancer. They are linked with long-term inflammation in the nose and sinuses.
Do biologics replace nasal sprays?
No. The US labels describe these biologics as add-on maintenance treatment, used together with standard care when CRSwNP is not controlled.
Sources for the last two answers: [1] [6, 7]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus Medical Encyclopedia: Nasal polyps
- DailyMed (US National Library of Medicine): Dupixent (dupilumab) US prescribing information, version published 7 August 2026
- Alfallaj et al. Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia. Saudi Med J 2023 (PubMed 37062559)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed (US National Library of Medicine): Nucala (mepolizumab) US prescribing information, version published 18 August 2025
- DailyMed (US National Library of Medicine): Xolair (omalizumab) US prescribing information, version published 20 August 2026
- DailyMed (US National Library of Medicine): Tezspire (tezepelumab-ekko) US prescribing information, version published 24 July 2026
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Severe asthma
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
This page is general health information, not medical advice. It does not replace a consultation with your doctor.